ALX Oncology Holdings Inc. has announced the initiation of its Phase 1 clinical development program for ALX2004, following clearance of its Investigational New Drug $(IND.AU)$ application by the U.S. Food and Drug Administration in April 2025. ALX2004, a novel EGFR-targeted antibody-drug conjugate, is set to enter Phase 1 trials in mid-2025. The trial will focus on dose escalation in patients with EGFR-expressing solid tumors, including non-small cell lung cancer, colorectal cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinoma. Initial safety data from the study is anticipated in the first half of 2026. ALX Oncology will provide further details on its clinical development plans and preclinical data in a webcast event. For more information, visit ALX Oncology's website.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。